Company Overview of Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company offers various cardio-cerebral vascular drugs, such as Oudimei to treat dysfunction caused by cardiac and brain diseases; Kelinao/Anjieli/Qingtong to treat cardio, cerebro, and peripheral vascular diseases; Yuanzhijiu to treat cardio-cerebral vascular diseases; GM1 to treat traumatic brain injuries, cerebral vascular accidents, and Parkinson’s disease; Guhong to treat cerebrovascular problems; and Yimaining to treat chronic arteriosclerosis obliterans, unstable angina, myocardial infarction, coronary ...
Zhubang 2000 Business Centre
Building 2, 21st Floor
Founded in 2001
Key Executives for Sihuan Pharmaceutical Holdings Group Ltd.
Deputy Chairman, Chief Executive Officer and Member of Nomination Committee
Total Annual Compensation: $16.0M
Co-Founder, Executive Chairman and Member of Remuneration Committee
Total Annual Compensation: $26.8M
Deputy General Manager of Sales & Marketing and Executive Director
Total Annual Compensation: $10.5M
Compensation as of Fiscal Year 2013.
Sihuan Pharmaceutical Holdings Group Ltd. Key Developments
Sihuan Pharmaceutical Holdings Group Ltd. Announces Delay in Publication of 2014 Annual Results
Mar 27 15
The Board of Sihuan Pharmaceutical Holdings Group Ltd. announced the shareholders of the company that the company is not able to publish the 2014 annual results on 31 March 2015 due to the fact that the auditors will not complete their audit of the company's financial statements in sufficient time.
Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2014 Results on Mar 31, 2015
Mar 19 15
Sihuan Pharmaceutical Holdings Group Ltd. announced that they will report fiscal year 2014 results on Mar 31, 2015
Sihuan Pharmaceutical Holdings Group Ltd., Board Meeting, Mar 31, 2015
Mar 19 15
Sihuan Pharmaceutical Holdings Group Ltd., Board Meeting, Mar 31, 2015., at 11:00 China Standard Time. Agenda: To consider and approve the annual results of the Company and its subsidiaries for the year ended December 31, 2014; and to consider the recommendation of the payment of final dividend.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries